Pharmafile Logo

Pharma Market Research Report – Predictions for 2016

PMR invited US President Harriet Kozak to submit her predictions for 2016

2016 will continue to see an increase in the number of requests for research projects investigating the market opportunity for rare disease and orphan drugs. Last year the FDA approved 48 drugs in rare diseases, including both novel and repurposed drugs.

Rare diseases are attractive to pharma for a number of reasons. Firstly, manufacturers of orphan drugs are awarded longer market exclusivity, reduced regulatory fees, tax incentives and line extensions. Secondly, although patient populations for each disease in every market are small, if the drug gains approval across a number of indications, the manufacturer can increase its potential revenue. Thirdly, if successful, manufacturers have the opportunity to be a market leader in a niche area.

Find out more:
www.researchpartnership.com/news/2016/01/pharma-market-research-report-predictions-for-2016/

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Guide

UX research

Article: Why pharma must trust the science of behaviour

In a recent interview with PME Magazine, Dan Coffin, Director explains why the application of behavioural science will be key to better health far beyond COVID-19.Read the full article here:...

Case study

Using qualitative conjoint to assess willingness-to-pay

Consumer health specialist joins Research Partnership Inc

Global healthcare market research consultancy Research Partnership has appointed Jennifer Stewart as a Director in their US offices in Philadelphia.

Article: What’s next? How behavioural science can support pharma’s future

Dan Coffin, Director explains why now is an opportune time for pharma marketers to embrace behavioural science. Read his latest article for PME Magazine.https://bit.ly/31ef6rh

Video: UX/ Experience design research

Director and UX expert Liza Pliss discusses Research Partnership's approach to user experience research and shares an example of a project where using design thinking led to an agile approach...

White paper: The impact of COVID-19 on chronic disease management

Therapy Watch, Research Partnership's syndicated PRF tracker, has been investigating the impact of COVID-19 on chronic disease management. In this white paper, Research Partnership share some of the insights and...

Article: Pricing a coronavirus vaccine

Using findings from Research Partnership's recent COVID-19 impact study, Market Access Directors Rachel Howard and Brett Gardiner and Consultant Suzan Serip explore the challenges of pricing a coronavirus vaccine. Read...

News: Living with Ulcerative Colitis and Crohn’s Disease

Living with Ulcerative Colitis (UC) and Crohn’s Disease (CD) are new patient syndicated reports which offer valuable insights into patient attitudes and behaviour towards their condition, treatments and unmet needs. These reports...

Interactive infographic

Living With: The journey from the patient’s perspective